Liu Wanchao, Yang Dianyu, Chen Longmei, Liu Qingqing, Wang Wenhui, Yang Zhenghua, Shang Anquan, Quan Wenqiang, Li Dong
Department of Clinical Laboratory, Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 201999, China.
Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.
J Cancer. 2020 Jun 15;11(16):4899-4906. doi: 10.7150/jca.45548. eCollection 2020.
This study investigated plasma exosomal miRNA-139-3p as a blood-based biomarker for the early diagnosis and metastasis monitoring of colorectal cancer (CRC). Exosome-rich fractions were isolated from the plasma of 80 CRC patients, and 23 controls using a kit method. We then used real-time polymerase chain reaction (RT-qPCR) to detect miR-139-3p levels in all subjects to evaluate expression levels and the predictive value of plasma exosomal miR-139-3p in CRC. We also collected clinicopathological data to explore correlations between abnormal miR-139-3p expression and clinicopathological parameters. When compared with healthy controls, exosomal miR-139-3p expression levels in CRC patients were significantly down-regulated. Furthermore, these expression levels were lower in metastatic colorectal cancer (mCRC) and submucosal patients. Receiver operating characteristic (ROC) curve analysis showed that exosomal miR-139-3p levels were differentiated between CRC patients and healthy controls, as well as between non-metastatic and metastatic patients. Our findings show that decreased exosomal miR-139-3p expression levels in CRC patient plasma may act as a novel biomarker for the early diagnosis and metastasis monitoring in CRC.
本研究调查了血浆外泌体miRNA-139-3p作为结直肠癌（CRC）早期诊断和转移监测的血液生物标志物。使用试剂盒方法从80例CRC患者和23例对照者的血浆中分离出富含外泌体的组分。然后，我们使用实时聚合酶链反应（RT-qPCR）检测所有受试者中miR-139-3p的水平，以评估血浆外泌体miR-139-3p在CRC中的表达水平和预测价值。我们还收集了临床病理数据，以探讨miR-139-3p异常表达与临床病理参数之间的相关性。与健康对照相比，CRC患者中外泌体miR-139-3p的表达水平显著下调。此外，这些表达水平在转移性结直肠癌（mCRC）和黏膜下患者中更低。受试者工作特征（ROC）曲线分析表明，外泌体miR-139-3p水平在CRC患者与健康对照之间以及非转移性和转移性患者之间存在差异。我们的研究结果表明，CRC患者血浆中外泌体miR-139-3p表达水平降低可能作为CRC早期诊断和转移监测的一种新型生物标志物。
